Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as the project was never initiated and no participants were enrolled.
- 12 Jan 2018 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2018.